Literature DB >> 20581077

Composite primary neuronal high-content screening assay for Huntington's disease incorporating non-cell-autonomous interactions.

Linda S Kaltenbach1, M McLean Bolton, Bijal Shah, Patrick M Kanju, Gwendolyn M Lewis, Gregory J Turmel, Jennifer C Whaley, O Joseph Trask, Donald C Lo.   

Abstract

Huntington's disease (HD) is a fatal neurodegenerative disease characterized by progressive cognitive, behavioral, and motor deficits and caused by expansion of a polyglutamine repeat in the Huntingtin protein (Htt). Despite its monogenic nature, HD pathogenesis includes obligatory non-cell-autonomous pathways involving both the cortex and the striatum, and therefore effective recapitulation of relevant HD disease pathways in cell lines and primary neuronal monocultures is intrinsically limited. To address this, the authors developed an automated high-content imaging screen in high-density primary cultures of cortical and striatal neurons together with supporting glial cells. Cortical and striatal neurons are transfected separately with different fluorescent protein markers such that image-based high-content analysis can be used to assay these neuronal populations separately but still supporting their intercellular interactions, including abundant synaptic interconnectivity. This assay was reduced to practice using transfection of a mutant N-terminal Htt domain and validated via a screen of ~400 selected small molecules. Both expected as well as novel candidate targets for HD emerged from this screen; of particular interest were target classes with close relative proximity to clinical testing. These findings suggest that composite primary cultures incorporating increased levels of biological complexity can be used for high-content imaging and "high-context" screening to represent molecular targets that otherwise may be operant only in the complex tissue environment found in vivo during disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20581077     DOI: 10.1177/1087057110373392

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  11 in total

1.  Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons.

Authors:  Andrew D Kraft; Linda S Kaltenbach; Donald C Lo; G Jean Harry
Journal:  Neurobiol Aging       Date:  2011-04-11       Impact factor: 4.673

2.  PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis.

Authors:  Audrey S Dickey; Dafne N Sanchez; Martin Arreola; Kunal R Sampat; Weiwei Fan; Nicolas Arbez; Sergey Akimov; Michael J Van Kanegan; Kohta Ohnishi; Stephen K Gilmore-Hall; April L Flores; Janice M Nguyen; Nicole Lomas; Cynthia L Hsu; Donald C Lo; Christopher A Ross; Eliezer Masliah; Ronald M Evans; Albert R La Spada
Journal:  Sci Transl Med       Date:  2017-12-06       Impact factor: 17.956

3.  Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration.

Authors:  Barbara Calamini; Donald C Lo; Linda S Kaltenbach
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

Review 4.  Functional genomic and high-content screening for target discovery and deconvolution.

Authors:  Susanne Heynen-Genel; Lars Pache; Sumit K Chanda; Jonathan Rosen
Journal:  Expert Opin Drug Discov       Date:  2012-08-04       Impact factor: 6.098

5.  Protein aggregation can inhibit clathrin-mediated endocytosis by chaperone competition.

Authors:  Anan Yu; Yoko Shibata; Bijal Shah; Barbara Calamini; Donald C Lo; Richard I Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-01       Impact factor: 11.205

6.  Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1.

Authors:  Amber L Southwell; Charles W Bugg; Linda S Kaltenbach; Denise Dunn; Stefanie Butland; Andreas Weiss; Paolo Paganetti; Donald C Lo; Paul H Patterson
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

7.  A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease.

Authors:  Daniel Todd; Ian Gowers; Simon J Dowler; Michael D Wall; George McAllister; David F Fischer; Sipke Dijkstra; Silvina A Fratantoni; Rhea van de Bospoort; Jessica Veenman-Koepke; Geraldine Flynn; Jamshid Arjomand; Celia Dominguez; Ignacio Munoz-Sanjuan; John Wityak; Jonathan A Bard
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

Review 8.  Increasing the Content of High-Content Screening: An Overview.

Authors:  Shantanu Singh; Anne E Carpenter; Auguste Genovesio
Journal:  J Biomol Screen       Date:  2014-04-07

9.  Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke.

Authors:  Michael J Van Kanegan; Denise E Dunn; Linda S Kaltenbach; Bijal Shah; Dong Ning He; Daniel D McCoy; Peiying Yang; Jiangnan Peng; Li Shen; Lin Du; Robert H Cichewicz; Robert A Newman; Donald C Lo
Journal:  Sci Rep       Date:  2016-05-12       Impact factor: 4.379

10.  Neuroprotective Effects of Annexin A1 Tripeptide after Deep Hypothermic Circulatory Arrest in Rats.

Authors:  Zhiquan Zhang; Qing Ma; Bijal Shah; G Burkhard Mackensen; Donald C Lo; Joseph P Mathew; Mihai V Podgoreanu; Niccolò Terrando
Journal:  Front Immunol       Date:  2017-08-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.